Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13725
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYeo, Dannel-
dc.contributor.authorHe, Hong-
dc.contributor.authorPatel, Oneel-
dc.contributor.authorLowy, Andrew M-
dc.contributor.authorBaldwin, Graham S-
dc.contributor.authorNikfarjam, Mehrdad-
dc.date.accessioned2016-01-22T03:39:11Z-
dc.date.accessioned2016-01-22T03:39:03Z-
dc.date.available2016-01-22T03:39:03Z-
dc.date.available2016-01-22T03:39:11Z-
dc.date.issued2016-01-16-
dc.identifier.citationBMC Cancer 2016; 16: 24en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/13725-
dc.description.abstractBACKGROUND: Pancreatic ductal adenocarcinoma remains one of the most lethal of all solid tumours. Treatment options are limited and gemcitabine-based chemotherapy remains the standard of care. Although growing evidence shows that p21-activated kinase 1 (PAK1) plays a crucial role in pancreatic cancer, its role has not been fully elucidated. This study aimed to characterise the expression and functional relevance of PAK1 in pancreatic cancer. METHODS: PAK1 expression was measured in pancreatic cancer specimens by immunohistochemistry and in pancreatic cancer cell lines by western blotting. The effect of inhibition of PAK1 by either shRNA knock-down (KD), or by a selective inhibitor, FRAX597, alone or in combination with gemcitabine, on cell proliferation and migration/invasion was measured by thymidine uptake and Boyden chamber assays, respectively. The effect on tumour growth and survival was assessed in orthotopic murine models. RESULTS: PAK1 was expressed in all human pancreatic cancer samples tested, an7d was upregulated in all pancreatic cancer cell lines tested. PAK1 KD inhibited pancreatic cancer cell growth and survival, and increased sensitivity to gemcitabine treatment. AKT activity and HIF1α expression were also inhibited. FRAX597 inhibited pancreatic cancer cell proliferation, survival, and migration/invasion. When combined with gemcitabine, FRAX597 synergistically inhibited pancreatic cancer proliferation in vitro and inhibited tumour growth in vivo. CONCLUSIONS: These results implicate PAK1 as a regulator of pancreatic cancer cell growth and survival. Combination of a PAK1 inhibitor such as FRAX597 with cytotoxic chemotherapy deserves further study as a novel therapeutic approach to pancreatic cancer treatment.-
dc.subjectPancreatic Neoplasmsen_US
dc.subjectDeoxycytidineen_US
dc.subjectPyridonesen_US
dc.titleFRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabineen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBMC Canceren_US
dc.identifier.affiliationDepartment of Surgery, Austin Health, the University of Melbourne, Heidelberg, VIC, Australiaen_US
dc.identifier.affiliationDepartment of Surgery, Division of Surgical Oncology, University of California at San Diego, Moores Cancer, La Jolla, CA, USAen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/26774265en_US
dc.identifier.doi10.1186/s12885-016-2057-zen_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-0944-8747-
dc.identifier.orcid0000-0003-4866-276X-
dc.type.austinJournal Articleen_US
local.name.researcherHe, Hong
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextWith Fulltext-
item.cerifentitytypePublications-
item.grantfulltextopen-
crisitem.author.deptSurgery (University of Melbourne)-
crisitem.author.deptSurgery (University of Melbourne)-
Appears in Collections:Journal articles
Files in This Item:
File Description SizeFormat 
art%3A10.1186%2Fs12885-016-2057-z.pdf2.76 MBAdobe PDFThumbnail
View/Open
Show simple item record

Page view(s)

22
checked on Mar 1, 2024

Download(s)

10
checked on Mar 1, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.